Explore the groundbreaking Phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax for CD123-positive AML patients, featuring promising safety and efficacy results.
Discover how maintenance therapy with Decitabine is revolutionizing AML treatment for older adults, particularly FLT3-ITD-negative patients, based on the landmark E2906 clinical trial.